Summary: This phase II, placebo controlled study in relapsing MS from Spain reports on the effects of treatment with fingolimod (Gilenya) on patient’s quality of life.
Data from the study supports a clinically important effect of fingolimod on health-related quality of life scores and on the fatigue/thinking HAQUAMS sub-domain. Similarly, BDI-II scores indicative of clinical depression favoured fingolimod over placebo at 6 months.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309